Then, to provide a more accurate measurement, we injected the B16F10 tumor-bearing mice with Flt3L for nine consecutive days and found that Flt3L administration increased the frequency of tumor-infiltrating CD103+ cDC1 in vivo, which represented the dominant myeloid cell population within the tumor (Fig. 7B and C). This evidence concerns the gene FLT3LG and neoplasm.